DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease

Completed

Conditions studied: Mild Cognitive Impairment

In brief

The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abnormal blood-based biomarker testing.

Key facts

Study ID

NCT05844488

Run by

Indiana University

People needed

26

Starts

2023-03-31

Expected to finish

2023-06-30

Last updated by the study team

2023-07-25

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be > 65 years of age
• Any gender
• Is an established or new patient at one of the 6 participating IUHP PC sites
• Is able to provide informed consent (research portion only for the biomarker consent) or has a Legally Authorized Representative (LAR) who can provide informed consent
• Has a "red" DCA screening in the last 12 months (a score of 0 or 1 out of 5)

You may not qualify if…

• Patients who do not complete a DCA screening for any reason
• Existing diagnosis of dementia documented in their medical record based on ICD-10 codes

Where it is running

• Indiana University Health Physicians Primary Care — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.